A Study of FCN-338 in Patients With Chronic CLL/SLL

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

April 28, 2024

Study Completion Date

December 31, 2024

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

FCN-338

FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.

Trial Locations (1)

SUN YAT-University Cancer Center, Guangzhou